The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies

Tabacchi, Elena; Fanti, Stefano; Nanni, Cristina

doi:10.1016/j.cpet.2016.02.011

Cited by 7 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also proven superior in detecting distant metastases (M‐stage), and shown to upstage both Ewings's sarcoma and osteosarcoma patients relative to CI . However, high‐resolution chest CT has higher sensitivity for detecting pulmonary metastases, particularly those less than 1 cm, and, therefore, diagnostic chest CT will remain an essential component of sarcoma staging and follow‐up.…”

Section: Applications Of Pet‐mri In Oncologic Musculoskeletal Diseasementioning

confidence: 99%

Applications of PET‐MRI in musculoskeletal disease

Kogan

Broski

Yoon

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Applications Of Pet‐mri In Oncologic Musculoskeletal Diseasementioning

confidence: 99%

Applications of PET‐MRI in musculoskeletal disease

Kogan

Broski

Yoon

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…The use of PET to assess disease biology at an individual level is now playing a pivotal role in personalized clinical decision making and further clinical management. [14][15][16] However, although the use of PET/CT is being increasingly used in patients with MPNST, its definite role within the clinical routine is still not delineated, partially because of the rarity of these tumors hindering prospective investigations with large patient groups. Here, the authors discuss the role and potential value of PET and PET/CT in regards to diagnosis, biopsy guidance, staging, and therapy response of PNT.…”

Section: Introductionmentioning

confidence: 99%

PET Imaging of Peripheral Nerve Tumors

et al. 2019

View full text Add to dashboard Cite

Malignant peripheral nerve sheath tumors (MPNST) are the sixth most frequent soft tissue sarcoma (STS), consisting of 5% to 10% of cases. Traditionally, MR imaging has been the main imaging modality to evaluate the extent and involvement of MPNT. The potential value of PET and PET/CT in regards to diagnosis, biopsy guidance, staging, and therapy response of MPNT are presented in the literature. Multimodality imaging with multiparametric hybrid PET/MR has also shown some utility in the management of peripheral nerve tumors (PNTs). Quantitative FDG-PET imaging used in combination with CT or MR imaging has shown great potential to discriminate benign from malignant PNTs.

show abstract

Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma

Breunis

Haveman

Vaarwerk

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma and can emerge throughout the whole body. For patients with newly diagnosed RMS, prognosis for survival depends on multiple factors such as histology, tumour site, and extent of the disease. Patients with metastatic disease at diagnosis have impaired prognosis compared to those with localised disease. Appropriate staging at diagnosis therefore plays an important role in choosing the right treatment regimen for an individual patient. Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is a functional molecular imaging technique that uses the increased glycolysis of cancer cells to visualise both structural information and metabolic activity. 18F-FDG-PET combined with computed tomography (CT) could help to accurately stage the extent of disease in patients with newly diagnosed RMS. In this review we aimed to evaluate whether 18F-FDG-PET could replace other imaging modalities for the staging of distant metastases in RMS. Objectives To determine the diagnostic accuracy of 18F-FDG-PET/CT imaging for the detection of bone, lung, and lymph node metastases in RMS patients at first diagnosis. Search methods We searched MEDLINE in PubMed (from 1966 to 23 December 2020) and Embase in Ovid (from 1980 to 23 December 2020) for potentially relevant studies. We also checked the reference lists of relevant studies and review articles; scanned conference proceedings; and contacted the authors of included studies and other experts in the field of RMS for information about any ongoing or unpublished studies. We did not impose any language restrictions. Selection criteria We included cross-sectional studies involving patients with newly diagnosed proven RMS, either prospective or retrospective, if they reported the diagnostic accuracy of 18F-FDG-PET/CT in diagnosing lymph node involvement or bone metastases or lung metastases or a combination of these metastases. We included studies that compared the results of the 18F-FDG-PET/CT imaging with those of histology or with evaluation by a multidisciplinary tumour board as reference standard. Data collection and analysis Two review authors independently performed study selection, data extraction, and methodological quality assessement according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). We analysed data for the three outcomes (nodal involvement and lung and bone metastases) separately. We used data from the 2 × 2 tables (consisting of true positives, false positives, true negatives, and false negatives) to calculate sensitivity and specificity in each study and corresponding 95% confidence intervals. We did not consider a formal meta-analysis to be relevant because of the small number of studies and substantial heterogeneity between studies. Main results Two studies met our inclusion criteria. The diagnostic accuracy of 18F-FDG-PET/CT was reported in both studies, which included a total of 36 participants. We considered both studies to be at high risk of bias for the do...

show abstract

The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies

Cited by 7 publications

References 64 publications

Applications of PET‐MRI in musculoskeletal disease

Applications of PET‐MRI in musculoskeletal disease

PET Imaging of Peripheral Nerve Tumors

Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma

Contact Info

Product

Resources

About